Rosemary Infusion for Hypertension With Hypertriglyceridemia

Rosemary Infusion for Hypertension With Hypertriglyceridemia: A Triglyceride-Stratified Clinical Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07352124

Enrollment

Registered

2026-01-20

Start date

2024-09-01

Completion date

2025-04-01

Last updated

2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension With Hypertriglyceridemia

Keywords

Rosemary infusion, hypertension , Hypertriglyceridemia

Brief summary

This study aimed to evaluate the effects of daily rosemary infusion consumption on blood pressure and lipid profile in patients with mild hypertension, stratified by triglyceride status. This 6-week open-label interventional study enrolled 47 patients with mild hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg). Participants were stratified into two groups: normal triglycerides, TG \<1.7 mmol/L, n=22 and high triglycerides, TG ≥1.7 mmol/L, n=25. Blood pressure was assessed using 24-hour ambulatory monitoring (Holter) at baseline and day 45. Comprehensive biochemical analysis included lipid profile, hepatic and renal function markers, and inflammatory parameters.

Interventions

DIETARY_SUPPLEMENTRosemary infusion

Rosemary infusion 100 ml during 45 days

DIETARY_SUPPLEMENTrosemary infusion

Rosemary infusion 100 ml during 45 days

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

Participants of both sexes, aged 18 years and older, were included in the study. The inclusion criteria were: (1) Presence of mild hypertension defined as systolic blood pressure (SBP) of 140-159 mmHg and/or diastolic blood pressure (DBP) of 90-99 mmHg according to the 2018 ESC/ESH guidelines(Williams et al., 2018); (2) No use of medications or dietary supplements for other health conditions.

Exclusion criteria

Participants were excluded if they had renal failure, autoimmune diseases, major gastrointestinal disorders, or a history of cardiovascular disease. Other

Design outcomes

Primary

Measure	Time frame
Blood pressure measurement	45 days
Evolution of serum triglycerides	45 days

Secondary

Measure	Time frame
Cardiovascular disease risk assessment	45 days
Atherogenic Index of Plasma	45 days

Countries

Tunisia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026